Corruption Laws Take Front Seat In Asian Deal Making Decisions And Expansion Plans
This article was originally published in PharmAsia News
Executive Summary
Multinational firms in Asia need to consider building independent in-house compliance teams to guard against mistakes in handling corruption cases, compliance and risk management, experts advise.
You may also be interested in...
Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations
While companies are feeling pressure to voluntarily disclose potential violations of the U.S. Foreign Corrupt Practices Act, it may not always be the most prudent action, former government attorneys suggested at a recent meeting
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.